Earnings Per Common Share Attributable to Common Shareholders (Tables)

6 Months Ended

Jul. 01, 2018

Schedule of Basic and Diluted Earning Per Share



The following table provides the detailed calculation of EPS:
	Three Months Ended				Six Months Ended
(IN MILLIONS)	July 1, 2018		July 2, 2017		July 1, 2018			July 2, 2017
EPS Numerator––Basic
Income from continuing operations	$	3,879	$	3,077	$	7,450		$	6,207
Less: Net income attributable to noncontrolling interests	7		5		16			14
Income from continuing operations attributable to Pfizer Inc.	3,872		3,071		7,434			6,193
Less: Preferred stock dividends––net of tax	—		—		1			—
Income from continuing operations attributable to Pfizer Inc. common shareholders	3,871		3,071		7,433			6,192
Discontinued operations––net of tax	—		2		(1		)	1
Net income attributable to Pfizer Inc. common shareholders	$	3,871	$	3,073	$	7,432		$	6,194
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$	3,872	$	3,071	$	7,434		$	6,193
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions	—		2		(1		)	1
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$	3,872	$	3,073	$	7,432		$	6,194
EPS Denominator
Weighted-average number of common shares outstanding––Basic	5,866		5,958		5,911			5,982
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements	86		80		93			83
Weighted-average number of common shares outstanding––Diluted	5,952		6,037		6,004			6,065
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans^(a)	3		47		2			47


^(a)	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.